4//SEC Filing
Posner Christopher 4
Accession 0001415889-24-002513
CIK 0001346830other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:26 PM ET
Size
7.7 KB
Accession
0001415889-24-002513
Insider Transaction Report
Form 4
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2024-02-01$0.55/sh−4,981$2,740→ 221,930 total - Award
Common Stock
2024-02-01+62,500→ 226,911 total
Footnotes (3)
- [F1]Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.
- [F2]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
- [F3]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Cara Therapeutics, Inc.
CIK 0001346830
Entity typeother
Related Parties
1- filerCIK 0001748265
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:26 PM ET
- Size
- 7.7 KB